Analysts Conflicted on These Healthcare Names: Lemaitre Vascular (LMAT), Catalyst Pharma (CPRX) and Nektar Therapeutics (NKTR)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lemaitre Vascular (LMAT – Research Report), ...
Hosted on MSN19h
Nektar completes enrolment in trial of rezpegaldesleukin for alopecia areata
Nektar Therapeutics has concluded target enrolment in the Phase IIb REZOLVE-AA trial of its investigational biologic therapy, ...
William Blair Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
William Blair analyst Andy Hsieh maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report) today. The ...
Zacks.com on MSN5h
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.40 per share a year ago. These ...
MarketWatch22h
Sarepta Therapeutics Inc.
Dyne Therapeutics Inc.-4.50% $1.4B ...